In a phase II clinical trial involving a combination of anti-PD-1 (avelumab), and the receptor kinase inhibitor drug (axitinib) targeting VEGFR showed an objective response rate (ORR) of 31.7% in chemotherapy-resistant and recurrent NSCLC [260]. This evidence concerns the gene KDR and non-small cell lung carcinoma.